Literature DB >> 28838111

Functional Outcome After Resection of Von Hippel-Lindau Disease-Associated Cauda Equina Hemangioblastomas: An Observational Cohort Study.

Gautam U Mehta1,2, Blake K Montgomery1, Dominic M Maggio1,2, Prashant Chittiboina1, Edward H Oldfield1,2, Russell R Lonser1,3.   

Abstract

BACKGROUND: Cauda equina hemangioblastomas in von Hippel-Lindau (VHL) disease can cause significant neurological signs and symptoms. Despite their associated morbidity, the management of these tumors remains incompletely defined.
OBJECTIVE: To determine optimal management, we analyzed the functional outcomes after resection of these tumors.
METHODS: VHL patients who underwent surgical resection of cauda equina hemangioblastomas at the National Institutes of Health and the University of Virginia were included. Clinical and radiological follow-up was performed at 6- to 12-month intervals after surgery.
RESULTS: Fifteen patients underwent 18 operations for 21 cauda equina hemangioblastomas (median follow-up 5.9 years). Patients often presented with multiple symptoms, including pain (67%), numbness (50%), urinary complaints (33%), and weakness (11%). Median preoperative tumor volume was 1.2 cm 3 . Four tumors at 3 operations were not resected due to a motor nerve root origin. Gross total resection was achieved in 14 surgeries (93% of operations when resection was attempted). New mild (non-function limiting) neurological symptoms were noted after 11 operations (61%), which most often (64%) resolved within 2 weeks of surgery. At 6-month follow-up, 15 patients (83%) were stable, 2 (11%) were improved, and 1 (6%) was worse. Histological analysis revealed that all tumors originated from within the involved nerve fascicle.
CONCLUSIONS: VHL-associated cauda equina hemangioblastomas have an intrafascicular origin and require interruption of the rootlet of origin for complete resection. Motor nerve root involvement may preclude complete resection but strategies including bony decompression and/or interruption of vascular supply may provide a therapeutic option. Nevertheless, most VHL patients with symptom-producing lesions improve with resection. Published by Oxford University Press on behalf of the Congress of Neurological Surgeons 2017.

Entities:  

Keywords:  Cauda equina; Hemangioblastoma; Lumbosacral; Nerve root; von Hippel-Lindau disease

Mesh:

Year:  2017        PMID: 28838111      PMCID: PMC6280992          DOI: 10.1093/ons/opx019

Source DB:  PubMed          Journal:  Oper Neurosurg (Hagerstown)        ISSN: 2332-4252            Impact factor:   2.703


  17 in total

1.  Hemangioblastoma of the L-5 nerve root. Case illustration.

Authors:  M Chazono; R Shiba; H Funasaki; S Soshi; A Hattori; K Fujii
Journal:  J Neurosurg       Date:  1999-01       Impact factor: 5.115

2.  Lumbar nerve root hemangioblastoma and iliac bone cyst in a patient with Von Hippel-Lindau disease.

Authors:  Zafer Orkun Toktaş; Akın Akakın; Deniz Konya; Yavuz Furuncuoglu; Mustafa Kemal Demir; Türker Kılıç
Journal:  Spine J       Date:  2015-08-31       Impact factor: 4.166

Review 3.  Hemangioblastomas of the lower spinal region: report of four cases with preoperative embolization and review of the literature.

Authors:  Alessandra Biondi; Giuseppe K Ricciardi; Tierry Faillot; Laurent Capelle; Rémy Van Effenterre; Jacques Chiras
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

4.  Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in von Hippel-Lindau disease.

Authors:  Kristin Huntoon; Tianxia Wu; J Bradley Elder; John A Butman; Emily Y Chew; W Marston Linehan; Edward H Oldfield; Russell R Lonser
Journal:  J Neurosurg       Date:  2015-10-30       Impact factor: 5.115

5.  Cauda equina hemangioblastoma at L5 vertebral level related to von Hippel-Lindau disease.

Authors:  Yuhao Sun; Qingfang Sun; Jiankang Shen; Huacheng Wu; Yongjing Guan; Kan Gong; Liuguan Bian
Journal:  Br J Neurosurg       Date:  2011-12-01       Impact factor: 1.596

Review 6.  Characterization of hemangioblastomas of spinal nerves.

Authors:  Sven Gläsker; Ansgar Berlis; Axel Pagenstecher; Vassilios I Vougioukas; Vera Van Velthoven
Journal:  Neurosurgery       Date:  2005-03       Impact factor: 4.654

7.  Volume of pituitary macroadenomas: assessment by MRI.

Authors:  P Lundin; F Pedersen
Journal:  J Comput Assist Tomogr       Date:  1992 Jul-Aug       Impact factor: 1.826

Review 8.  Stereotactic radiosurgery for hemangiomas and ependymomas of the spinal cord.

Authors:  Stephen I Ryu; Daniel H Kim; Steven D Chang
Journal:  Neurosurg Focus       Date:  2003-11-15       Impact factor: 4.047

9.  Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease.

Authors:  Russell R Lonser; John A Butman; Kristin Huntoon; Ashok R Asthagiri; Tianxia Wu; Kamran D Bakhtian; Emily Y Chew; Zhengping Zhuang; W Marston Linehan; Edward H Oldfield
Journal:  J Neurosurg       Date:  2014-02-28       Impact factor: 5.115

Review 10.  Proximal nerve root spinal hemangioblastomas: presentation of three cases, MR appearance, and literature review.

Authors:  Edward J Escott; B K Kleinschmidt-DeMasters; Kerry Brega; Kevin O Lillehei
Journal:  Surg Neurol       Date:  2004-03
View more
  3 in total

1.  Intradural, extramedullary hemangioblastoma at the level of the conus medullaris: illustrative case.

Authors:  Lisa B E Shields; John E Harpring; Hilary A Highfield; Yi Ping Zhang; Christopher B Shields
Journal:  J Neurosurg Case Lessons       Date:  2021-04-26

Review 2.  Sporadic hemangioblastoma of cauda equina: A case report and brief literature review.

Authors:  Salvatore D' Oria; David Giraldi; Daniel Andres Alvarado Flores; Domenico Murrone; Vincenzo D' Angelo; Bipin Chaurasia
Journal:  J Craniovertebr Junction Spine       Date:  2022-09-14

3.  Sporadic hemangioblastoma of cauda equina: An atypical case report.

Authors:  Henrique Oliveira Martins; Roger Schmidt Brock; Mario Augusto Taricco; José Francisco Pereira Júnior; Matheus Fernandes de Oliveira
Journal:  Surg Neurol Int       Date:  2019-04-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.